Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 14/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 2/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490507 | 0.85 | TDP1 (0.39) | L3MBTL1RAB9A | |
| SCHEMBL6490954 | 0.79 | TSHR (0.42) | DCTPP1L3MBTL1GALR3NR2F2RAB9A | |
| SCHEMBL6491201 | 0.76 | MCL1 (0.43) | — | |
| SCHEMBL6498538 | 0.75 | DCTPP1 (0.44) | DCTPP1L3MBTL1GALR3NR2F2RAB9A | |
| SCHEMBL6487328 | 0.74 | RXRA (0.40) | DCTPP1 | |
| SCHEMBL6502360 | 0.74 | PABPC1 (0.39) | — | |
| SCHEMBL6501927 | 0.72 | GPR35 (0.35) | DCTPP1L3MBTL1HSD17B13 | |
| SCHEMBL6501064 | 0.72 | PIK3C2B (0.38) | DCTPP1 | |
| SCHEMBL6491005 | 0.72 | BCL2 (0.47) | — | |
| SCHEMBL6490020 | 0.71 | DCTPP1 (0.39) | DCTPP1HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DCTPP1 1534/4885L3MBTL1 790/4885PDE10A 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.